(800) 574 – 6320
Request a call back
-
Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech…
-
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 101.7% during the first three quarters of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same…
-
Mentor Capital Enters Medical Marijuana Field to Combat Cancer Wasting
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has initiated investment in the Medical Marijuana market. “The ‘munchies’ are a godsend to cancer sufferers who just stop eating food that tastes like wood and leaves them nauseous,” explains Mentor CEO, Chester Billingsley. “In the days of clans and caves, elders…
-
Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now. The purpose of…
-
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the…
-
Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index…
-
Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and Adds Companies for 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7%…
-
Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 47.3% during the first quarter of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first…
-
Mentor Capital Reports Mid-Year Profits for 2011
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) today reported financial results for the semi-annual period ending June 30, 2011. The company announced earnings of $0.04 per basic and diluted share for the six-month period. The six months of earnings, which calculates to an $0.08 per share annualized rate, follows the $0.09 per basic share …
-
Mentor Capital Cancer Immunotherapy Index Outpaces Biotechs on Second Anniversary
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 85.30% during the twenty-four months since its creation on July 10, 2009. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE…